Chiasma (NASDAQ: CHMA) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its rivals? We will compare Chiasma to similar businesses based on the strength of its institutional ownership, profitability, dividends, analyst recommendations, valuation, risk and earnings.
Volatility & Risk
Chiasma has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Chiasma’s rivals have a beta of 1.12, indicating that their average share price is 12% more volatile than the S&P 500.
Earnings and Valuation
This table compares Chiasma and its rivals revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Chiasma Competitors||$604.20 million||$110.82 million||56.05|
Chiasma’s rivals have higher revenue and earnings than Chiasma. Chiasma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and recommmendations for Chiasma and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biopharmaceuticals” companies have a potential upside of 15.85%. Given Chiasma’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Chiasma has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
50.3% of Chiasma shares are owned by institutional investors. Comparatively, 45.8% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 3.8% of Chiasma shares are owned by insiders. Comparatively, 16.5% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Chiasma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Chiasma rivals beat Chiasma on 8 of the 12 factors compared.
Chiasma Company Profile
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.